A recent international study has revealed remarkable outcomes from a new cancer treatment that has the potential to eradicate tumours in patients whose cancers had become resistant to conventional therapies. The trial, which spanned across 11 countries, focused on the injection known as amivantamab, demonstrating unprecedented efficacy in a group of patients grappling with advanced head and neck cancers.
Promising Results from the OrigAMI-4 Trial
The OrigAMI-4 trial, conducted at the Royal Marsden Hospital, enrolled 102 participants suffering from head and neck cancer—an affliction that ranks as the sixth most common cancer globally. The findings, which will be presented at the upcoming American Society of Clinical Oncology (ASCO) conference in Chicago, indicate that over a third of the patients experienced significant tumour shrinkage, with 15 individuals achieving complete tumour eradication.
Professor Kevin Harrington, a prominent figure in biological cancer therapies at the Institute of Cancer Research, London, expressed excitement over the findings: “These are unprecedentedly strong responses in patients whose disease has become resistant to both chemotherapy and immunotherapy. This is a group of patients for whom treatment options are extremely limited, so seeing this level of benefit is very striking.”
How Amivantamab Works
Amivantamab operates through a triple-action mechanism that targets cancer cells in multiple ways. It inhibits the epidermal growth factor receptor (EGFR) and the MET pathway, both of which are crucial for tumour growth and survival. Additionally, by stimulating the immune system, the jab encourages the body to actively fight against the malignancy.
The treatment is administered as a small injection under the skin, allowing for a more convenient and quicker process compared to traditional intravenous methods. This innovation is particularly beneficial for outpatient settings, where time and comfort are paramount.
Patient Experiences Highlight Treatment’s Impact
Carl Walsh, a 56-year-old participant from Birmingham, shared his journey with tongue cancer since his diagnosis in May 2024. After failing to respond to chemotherapy and immunotherapy, he joined the trial in July 2025. Now on his 17th cycle of amivantamab, Walsh reflects on the transformation he has experienced: “I now feel able to live a normal life. Before starting the trial, I struggled to speak properly and found eating difficult because of the swelling and pain.”
Walsh reported a notable reduction in swelling and pain following the treatment, which has allowed him to return to a more normal diet, including enjoying a long-awaited steak. His speech has also improved, enabling him to communicate effectively at work.
The Broader Implications for Cancer Treatment
The research team noted that their focus on head and neck cancers not linked to human papillomavirus (HPV) is particularly significant. These types of cancers are generally more difficult to treat, and advances in this area could lead to improved outcomes for a patient population that often faces grim prognoses.
Patients receiving amivantamab showed a median survival of 12.5 months after beginning the treatment, a remarkable outcome given the challenging nature of their conditions. Professor Kristian Helin, CEO of the Institute of Cancer Research, remarked on the importance of these findings: “This study demonstrates how the development of new treatments through rigorous cancer research may lead to meaningful advances, even for patients with very limited treatment options.”
Why it Matters
The emergence of amivantamab as a viable treatment option offers new hope to those battling advanced cancer, particularly for patients who have exhausted traditional therapies. As the medical community eagerly anticipates further studies and wider implementation, this breakthrough underscores the importance of continued investment in cancer research. The potential to significantly improve quality of life and survival rates for patients facing dire circumstances cannot be overstated.
